0.2% Heparin Sodium Solution in PBS

<strong>0.2% Heparin Sodium Solution in PBS</strong>_x000D_ <strong>Catalog number:</strong> B2010136_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Volume/Weight:</strong> 5 x 1 mL_x000D_ <strong>pH:</strong> 7.4_x000D_ <strong>Supplied as:</strong> Ready-to-use solution_x000D_ <strong>Appearance:</strong> Clear solution_x000D_ <strong>Applications:</strong> Optimized solution for applications using Heparin: mucopolysaccharide with anticoagulant properties as well as cellular biology function such as binding of fibroblast growth factor (FGF) to its receptor._x000D_ <strong>Storage:</strong> 2-8°C_x000D_ <strong>Keywords:</strong> Heparin PBS, Heparin culture medium_x000D_ <strong>Grade:</strong> Biotechnology grade. All components are highly pure (minimum 99%). All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered on a 0.22 um._x000D_ _x000D_ <strong>About Heparin</strong>_x000D_ _x000D_ Heparin is a naturally occurring glycoaminoglycan with anti coagulant (blood thinner) properties._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Cassinelli G, Naggi A. Old and new applications of non-anticoagulant heparin._x000D_ Int J Cardiol. 2016 Jun;212 Suppl 1:S14-21._x000D_ 2: Pucher PH, Cummings IG, Shipolini AR, McCormack DJ. Is heparin needed for_x000D_ patients with an intra-aortic balloon pump? Interact Cardiovasc Thorac Surg._x000D_ 2012 Jul;15(1):136-9._x000D_ _x000D_ 3: Torri G, Cassinelli G. Looking Forward to the Future of Heparin: New Sources,_x000D_ Developments and Applications. Molecules. 2018 Jan 31;23(2):293._x000D_ 4: Liu X, St Ange K, Wang X, Lin L, Zhang F, Chi L, Linhardt RJ. Parent heparin_x000D_ and daughter LMW heparin correlation analysis using LC-MS and NMR. Anal Chim_x000D_ Acta. 2017 Apr 8;961:91-99._x000D_ 5: Masuko S, Linhardt RJ. Chemoenzymatic synthesis of the next generation of_x000D_ ultralow MW heparin therapeutics. Future Med Chem. 2012 Mar;4(3):289-96._x000D_ 6: Walenga JM, Lyman GH. Evolution of heparin anticoagulants to ultra-low-_x000D_ molecular-weight heparins: a review of pharmacologic and clinical differences_x000D_ and applications in patients with cancer. Crit Rev Oncol Hematol. 2013_x000D_ Oct;88(1):1-18._x000D_ 7: Hoppensteadt D, Walenga JM, Fareed J, Bick RL. Heparin, low-molecular-weight_x000D_ heparins, and heparin pentasaccharide: basic and clinical differentiation._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/12627673/">Hematol Oncol Clin North Am</a>. 2003 Feb;17(1):313-41._x000D_ _x000D_ <strong>Products Related to 0.2% Heparin Sodium Solution in PBS: </strong> <a>Biochemical Buffers and Solutions</a>